In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF)

Faulhaber, M.; W├Ârmann, B.; Ganser, A.; Verbeek, W.
December 2002
Annals of Hematology;Dec2002, Vol. 81 Issue 12, p695
Academic Journal
To evaluate a potential therapeutic role for megakaryocyte growth and development factor (MGDF) in myelodysplastic syndromes (MDS) we compared the in vitro response of normal and myelodysplastic megakaryopoiesis to MGDF on bone marrow mononuclear cells from nine MDS patients and four healthy donors in a short term liquid culture system. The cells were incubated with MGDF alone (1 ng/ml, 10 ng/ml and 100 ng/ml) and in combination with 20 ng/ml stem cell factor, 2 U/ml erythropoietin (EPO) and 100 ng/ml interleukin-3 (IL-3). Cytospins were prepared after 4 days and 10 days for CD61 APAAP staining. In addition, the ploidy of propidium iodide stained CD61 positive cells were detected by flow cytometry. The CD61+ cell number significantly increased (13-fold after 4 days, 56-fold after 10 days of culture) when MGDF (100 ng/ml) was added to the normal bone marrow (NBM) cultures (P=0.0003; P=0.0001). In the MDS cultures the absolute number of endomitotic cells as well as the percentage of polyploid cells remained significantly lower than in NBM after 10 days (P=0.0001). The effect of MGDF on polyploidization of MDS cells was significantly dose dependent (P=0.0051). We found no correlation between peripheral platelet count, cellularity of the bone marrow, number of bone marrow megakaryocytes or FAB-subtype and response to MGDF. Additional administration of IL-3 resulted in a left-shift of megakaryopoiesis in both groups. Even though the response of myelodysplastic megakaryocytic progenitors to MGDF shows inter-individual variations, it is significantly impaired overall. Our data suggest that higher doses of MGDF may be able to ameliorate thrombocytopenia in a subgroup of MDS patients.


Related Articles

  • Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes. Poloni, A; Maurizi, G; Mattiucci, D; Amatori, S; Fogliardi, B; Costantini, B; Mariani, M; Mancini, S; Olivieri, A; Fanelli, M; Leoni, P // Leukemia (08876924);Nov2014, Vol. 28 Issue 11, p2241 

    The article focuses on the evidence that changes to the direct interaction between hematopoietic stem cells (HSCs) and stroma contribute to abnormal HSC growth and maturation. The use of flow cytometry to compare the expression of molecules that have important functions in cell adhesion such as...

  • Kinase inhibitors: A molecular target for myelodysplastic syndromes. Tse, Man Tsuey // Nature Reviews Drug Discovery;Sep2013, Vol. 12 Issue 9, p664 

    The article discusses the potentials of interleukin-1 receptor-associated kinase 1 (IRAK1) as druggable target for myelodysplastic syndromes (MDSs). It references the study by Starczynowki and colleagues. The authors confirmed the overexpression and activation of IRAK1 in MDS CD34+ bone marrow...

  • Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. Kitagawa, M; Takahashi, M; Yamaguchi, S; Inoue, M; Ogawa, S; Hirokawa, K; Kamiyama, R // Leukemia (08876924);May99, Vol. 13 Issue 5, p699 

    Nitric oxide (NO) is a biological mediator which is synthesized from L-arginine by a family of nitric oxide synthases (NOS). We have studied the expression of the inducible NOS (iNOS) by bone marrow cells from the patients with myelodysplastic syndromes (MDS) at the mRNA level by RT-PCR assay...

  • Marrow mesenchymal stem cells transduced with TPO/FL genes as support for ex vivo expansion of hematopoietic stem/progenitor cells. Xie, C.-G.; Wang, J.-F.; Xiang, Y.; Jia, B.-B.; Qiu, L.-Y.; Wang, L.-J.; Wang, G.-Z.; Huang, G.-P. // Cellular & Molecular Life Sciences;Nov2005, Vol. 62 Issue 21, p2495 

    A new marrow-derived mesenchymal stem cell (hMSC) line that could support expansion of hematopoietic stem/progenitor cells (HSPCs) was developed. Primary hMSCs were infected with retrovirus containing Flt-3 ligand and thrombopoietin genes. CD34+ cells from cord blood were expanded with primary...

  • Megakaryocytes in the hematopoietic stem cell niche. Day, Ryan B.; Link, Daniel C. // Nature Medicine;Nov2014, Vol. 20 Issue 11, p1233 

    The article discusses hematopoietic stem cell niche through megakaryocytes which regulates hematopoietic stem cell quiescence and functions. Topics discussed include quiescent hematopoietic stem cell are found endosteum, megakaryocytes are found to be rich in Transforming growth factor beta...

  • High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human Megakaryocytes. Currao, Manuela; Balduini, Carlo L.; Balduini, Alessandra; Lin, Baochuan // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Background: Romiplostim (AMG531) is a Thrombopoietin (TPO) receptor agonist with no homology with the endogenous TPO that has been used to treat patients affected by immune thrombocytopenia (ITP). Despite the use of TPO mimetics in the clinical practice, the mechanisms underlying their impact on...

  • GCSF-R Expression in Myelodysplastic and Myeloproliferative Disorders and Blast Dysmaturation in CML. Hanumanthu, Vidya Sagar; Pirruccello, Samuel J. // American Journal of Clinical Pathology;Aug2013, Vol. 140 Issue 2, p155 

    Objectives: To characterize granulocyte colony-stimulating factor receptor (CD114) expression in normal (n = 20), myelodysplastic (n = 34), and chronic myelogenous leukemia (CML; n = 5) bone marrow by flow cytometry. Methods: Clinical bone marrow samples were analyzed using...

  • Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. Jensen, Brenda A.; Leeman, Rebecca J.; Schlezinger, Jennifer J.; Sherr, David H. // Environmental Health: A Global Access Science Source;2003, Vol. 2, p16 

    Background: Bone marrow stromal cells produce cytokines required for the normal growth and development of all eight hematopoietic cell lineages. Aberrant cytokine production by stromal cells contributes to blood cell dyscrasias. Consequently, factors that alter stromal cell cytokine production...

  • Bone Marrow Cells Enhance Liver Regeneration After Massive Hepatectomy in Mice. Kaibori, Masaki; Adachi, Yasushi; Shimo, Tomohiko; Ishizaki, Morihiko; Matsui, Kosuke; Tanaka, Yoshito; Ohishi, Masaharu; Araki, Yoshiro; Tokuhara, Katsuji; Okumura, Tadayoshi; Nishizawa, Mikio; Kwon, A-Hon // Digestive Diseases & Sciences;Jul2014, Vol. 59 Issue 7, p1484 

    Background: Recent evidence indicates that transplanted autologous bone marrow cells (BMCs) can be converted into functional liver cells. BMC therapy can improve hepatic function and increase the potential for liver regeneration in patients with serious liver damage. We investigated whether BMC...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics